Neogen Corporation
HealthcareNASDAQ:NEOG · NASDAQ Global Select
-$0.15 today
Vol 1.23M · Avg 2.60M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$870.5M of revenue converted into -$608.8M of net income for the selected period. Gross margin is 42.5% and net margin is -67.3%, showing how much revenue survives after costs and taxes. EPS is $-2.80, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $894.7M -3.2% | $924.2M +12.4% | $822.4M +56.0% | $527.2M +12.5% | $468.5M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $473.3M +2.5% | $461.6M +10.8% | $416.5M +46.6% | $284.1M +12.1% | $253.4M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $421.4M -8.9% | $462.6M +14.0% | $406.0M +67.1% | $243.0M +13.0% | $215.1M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 47.1% -3.0pp | 50.1% +0.7pp | 49.4% +3.3pp | 46.1% +0.2pp | 45.9% | 9.8% | 28.9% | 38.3% |
| Research & Development | $21.1M -6.2% | $22.5M -13.7% | $26.0M +52.7% | $17.0M +4.9% | $16.2M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $402.0M +5.0% | $382.8M +11.8% | $342.4M +104.6% | $167.3M +34.3% | $124.6M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $412.0M +6.9% | $385.2M +4.6% | $368.4M +99.8% | $184.4M +30.9% | $140.9M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $125.7M +3.7% | $121.2M +37.2% | $88.4M +273.0% | $23.7M +12.6% | $21.0M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$937.8M -613.6% | $182.6M +49.3% | $122.3M +45.8% | $83.9M -12.9% | $96.3M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -104.8% -124.6pp | 19.8% +4.9pp | 14.9% -1.0pp | 15.9% -4.6pp | 20.6% | 5.6% | 46.3% | 42.0% |
| Operating Income | $9.4M -87.8% | $77.4M +106.4% | $37.5M -36.0% | $58.6M -21.0% | $74.2M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 1.1% -7.3pp | 8.4% +3.8pp | 4.6% -6.6pp | 11.1% -4.7pp | 15.8% | 16.6% | 24.1% | 22.0% |
| Interest Income | $3.1M -51.1% | $6.4M +100.9% | $3.2M +136.4% | $1.3M -20.9% | $1.7M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $71.6M -2.4% | $73.4M +31.2% | $56.0M +77623.6% | $72.0K -7.7% | $78.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$1.1B -1145.5% | -$91.7M -54.0% | -$59.6M -3848.1% | $1.6M +44.6% | $1.1M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$1.1B -7821.1% | -$14.3M +35.1% | -$22.0M -136.6% | $60.2M -20.0% | $75.3M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -126.7% -125.1pp | -1.5% +1.1pp | -2.7% -14.1pp | 11.4% -4.6pp | 16.1% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$41.1M -740.8% | -$4.9M -689.9% | $828.0K -93.0% | $11.9M -17.3% | $14.4M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$1.1B -11491.6% | -$9.4M +58.8% | -$22.9M -147.3% | $48.3M -20.7% | $60.9M | $4.9B | $4.8B | $4.7B |
| Net Margin | -122.1% -121.0pp | -1.0% +1.8pp | -2.8% -11.9pp | 9.2% -3.8pp | 13.0% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$5 -11463.2% | -$0 +63.8% | -$0 -126.7% | $0 -21.1% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$5 -11463.2% | -$0 +63.8% | -$0 -126.7% | $0 -21.1% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $216.9M +0.2% | $216.5M +14.6% | $188.9M +75.4% | $107.7M +1.1% | $106.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $216.9M +0.2% | $216.5M +14.6% | $188.9M +74.9% | $108.0M +0.8% | $107.1M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
NovoCure Limited
NASDAQ:NVCR
$2.06B
Intellia Therapeutics, Inc.
NASDAQ:NTLA
$1.36B
BioLife Solutions, Inc.
NASDAQ:BLFS
$1.28B
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
$1.22B
OPKO Health, Inc.
NASDAQ:OPK
$1.07B
CONMED Corporation
NYSE:CNMD
$1.05B
Azenta, Inc.
NASDAQ:AZTA
$1.04B
Zenas BioPharma, Inc.
NASDAQ:ZBIO
$883.93M
Tilray Brands, Inc.
NASDAQ:TLRY
$595.63M
Upstream Bio, Inc.
UPB
$331.96M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does NEOG generate?
Neogen Corporation (NEOG) reported $894.66M of revenue in fiscal 2025.
Is NEOG profitable?
Neogen Corporation (NEOG) reported -$1,092,044,000.00 of net income, with a net margin of -122.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.